SK5402003A3 - Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors - Google Patents
Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors Download PDFInfo
- Publication number
- SK5402003A3 SK5402003A3 SK540-2003A SK5402003A SK5402003A3 SK 5402003 A3 SK5402003 A3 SK 5402003A3 SK 5402003 A SK5402003 A SK 5402003A SK 5402003 A3 SK5402003 A3 SK 5402003A3
- Authority
- SK
- Slovakia
- Prior art keywords
- alkyl
- substituted
- amino
- methyl
- aryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24987700P | 2000-11-17 | 2000-11-17 | |
US31056101P | 2001-08-07 | 2001-08-07 | |
PCT/US2001/049982 WO2002040486A2 (en) | 2000-11-17 | 2001-11-07 | METHODS OF TREATING p38 KINASE-ASSOCIATED CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS |
Publications (1)
Publication Number | Publication Date |
---|---|
SK5402003A3 true SK5402003A3 (en) | 2004-06-08 |
Family
ID=26940426
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK540-2003A SK5402003A3 (en) | 2000-11-17 | 2001-11-07 | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors |
Country Status (32)
Country | Link |
---|---|
EP (1) | EP1363910B1 (hu) |
JP (1) | JP2004522713A (hu) |
KR (1) | KR100847605B1 (hu) |
CN (1) | CN1622946A (hu) |
AR (1) | AR032637A1 (hu) |
AT (1) | ATE318820T1 (hu) |
AU (2) | AU2002232760B2 (hu) |
BG (1) | BG107750A (hu) |
BR (1) | BR0115446A (hu) |
CA (1) | CA2429628A1 (hu) |
CY (1) | CY1105250T1 (hu) |
CZ (1) | CZ20031370A3 (hu) |
DE (1) | DE60117607T2 (hu) |
DK (1) | DK1363910T3 (hu) |
EE (1) | EE200300227A (hu) |
ES (1) | ES2259051T3 (hu) |
GE (1) | GEP20063915B (hu) |
HK (1) | HK1057555A1 (hu) |
HR (1) | HRP20030485A2 (hu) |
HU (1) | HUP0303897A2 (hu) |
IL (1) | IL155570A0 (hu) |
IS (1) | IS6816A (hu) |
MX (1) | MXPA03004290A (hu) |
MY (1) | MY127066A (hu) |
NO (1) | NO20032229L (hu) |
NZ (1) | NZ525334A (hu) |
PE (1) | PE20020819A1 (hu) |
PL (1) | PL366376A1 (hu) |
PT (1) | PT1363910E (hu) |
SK (1) | SK5402003A3 (hu) |
WO (1) | WO2002040486A2 (hu) |
YU (1) | YU37903A (hu) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6867300B2 (en) | 2000-11-17 | 2005-03-15 | Bristol-Myers Squibb Company | Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors |
EP1401416B1 (en) | 2001-06-29 | 2006-10-25 | AB Science | Use of c-kit inhibitors for treating inflammatory bowel diseases (ibd) |
WO2003003006A2 (en) | 2001-06-29 | 2003-01-09 | Ab Science | New potent, selective and non toxic c-kit inhibitors |
WO2003002105A2 (en) * | 2001-06-29 | 2003-01-09 | Ab Science | Use of tyrosine kinase inhibitors for treating bone loss |
WO2003002108A2 (en) | 2001-06-29 | 2003-01-09 | Ab Science | Use of tyrosine kinase inhibitors for treating inflammatory diseases |
CA2452371A1 (en) | 2001-06-29 | 2003-01-09 | Ab Science | Use of tyrosine kinase inhibitors for treating allergic diseases |
GB0124933D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
EP1864975B1 (en) | 2002-02-12 | 2010-10-20 | GlaxoSmithKline LLC | Nicotinamide derivates useful as P38 inhibitors |
BR0307631A (pt) | 2002-02-14 | 2004-12-21 | Pharmacia Corp | Piridinonas substituìdas como moduladores de p38 map-quinase |
US6900208B2 (en) | 2002-03-28 | 2005-05-31 | Bristol Myers Squibb Company | Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders |
US7388009B2 (en) | 2002-04-23 | 2008-06-17 | Bristol-Myers Squibb Company | Heteroaryl-substituted pyrrolo-triazine compounds useful as kinase inhibitors |
SI1497019T1 (sl) * | 2002-04-23 | 2015-08-31 | Bristol-Myers Squibb Company | Pirolo-triazin anilin spojine uporabne kot inhibitorji kinaze |
PL373371A1 (en) | 2002-04-23 | 2005-08-22 | Bristol-Myers Squibb Company | Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors |
TWI329112B (en) | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
US6933386B2 (en) * | 2002-07-19 | 2005-08-23 | Bristol Myers Squibb Company | Process for preparing certain pyrrolotriazine compounds |
EP1543009A4 (en) * | 2002-08-02 | 2007-08-08 | Bristol Myers Squibb Co | Pyrrolotriazine KINASE INHIBITORS |
TW200420565A (en) * | 2002-12-13 | 2004-10-16 | Bristol Myers Squibb Co | C-6 modified indazolylpyrrolotriazines |
CA2513081C (en) * | 2003-01-09 | 2011-04-19 | Astellas Pharma Inc. | Pyrrolopyridazine derivatives |
CA2515218A1 (en) * | 2003-02-05 | 2004-08-26 | Bristol-Myers Squibb Company | Process for preparing pyrrolotriazine kinase inhibitors |
GB0308201D0 (en) | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
GB0308186D0 (en) | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
EP1635824B1 (en) | 2003-06-03 | 2009-08-19 | Novartis AG | 5-membered heterocycle-based p-38 inhibitors |
PL1641764T3 (pl) | 2003-06-26 | 2011-12-30 | Novartis Ag | Inhibitory kinazy P38 na bazie 5-członowych heterocykli |
DE602004017494D1 (de) | 2003-07-25 | 2008-12-11 | Novartis Ag | Inhibitoren von p-38-kinase |
GB0318814D0 (en) | 2003-08-11 | 2003-09-10 | Smithkline Beecham Corp | Novel compounds |
US7419978B2 (en) | 2003-10-22 | 2008-09-02 | Bristol-Myers Squibb Company | Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors |
US7102001B2 (en) | 2003-12-12 | 2006-09-05 | Bristol-Myers Squibb Company | Process for preparing pyrrolotriazine |
AU2004309420B2 (en) * | 2003-12-23 | 2008-10-30 | Novartis Ag | Bicyclic heterocyclic p-38 kinase inhibitors |
US7064203B2 (en) | 2003-12-29 | 2006-06-20 | Bristol Myers Squibb Company | Di-substituted pyrrolotriazine compounds |
MY145634A (en) | 2003-12-29 | 2012-03-15 | Bristol Myers Squibb Co | Pyrrolotriazine compounds as kinase inhibitors |
US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
TW200538453A (en) | 2004-04-26 | 2005-12-01 | Bristol Myers Squibb Co | Bicyclic heterocycles as kinase inhibitors |
UY28931A1 (es) * | 2004-06-03 | 2005-12-30 | Bayer Pharmaceuticals Corp | Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis |
US7102002B2 (en) | 2004-06-16 | 2006-09-05 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
US7432373B2 (en) | 2004-06-28 | 2008-10-07 | Bristol-Meyers Squibb Company | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors |
US7439246B2 (en) | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
US7173031B2 (en) | 2004-06-28 | 2007-02-06 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
US7102003B2 (en) | 2004-07-01 | 2006-09-05 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds |
US7504521B2 (en) | 2004-08-05 | 2009-03-17 | Bristol-Myers Squibb Co. | Methods for the preparation of pyrrolotriazine compounds |
US7148348B2 (en) | 2004-08-12 | 2006-12-12 | Bristol-Myers Squibb Company | Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors |
US7151176B2 (en) | 2004-10-21 | 2006-12-19 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds |
KR20070064350A (ko) | 2004-10-26 | 2007-06-20 | 노파르티스 아게 | C-jun n 말단 키나제 (jnk) 및 p-38 키나제억제제로서의 피롤로[1,2-d][1,2-4]트리아진 |
US7405213B2 (en) * | 2005-07-01 | 2008-07-29 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith |
US7402582B2 (en) * | 2005-07-01 | 2008-07-22 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith |
US7880004B2 (en) | 2005-09-15 | 2011-02-01 | Bristol-Myers Squibb Company | Met kinase inhibitors |
US7547782B2 (en) | 2005-09-30 | 2009-06-16 | Bristol-Myers Squibb Company | Met kinase inhibitors |
US7514435B2 (en) | 2005-11-18 | 2009-04-07 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
US7348325B2 (en) | 2005-11-30 | 2008-03-25 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
US8063208B2 (en) | 2006-02-16 | 2011-11-22 | Bristol-Myers Squibb Company | Crystalline forms of (3R,4R)-4-amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol |
US8268998B2 (en) | 2006-11-03 | 2012-09-18 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
US7982033B2 (en) | 2006-11-03 | 2011-07-19 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
ES2539620T3 (es) | 2008-12-19 | 2015-07-02 | Cephalon, Inc. | Pirrolotriazina como inhibidor de ALK y de JAK2 |
WO2010120963A1 (en) * | 2009-04-16 | 2010-10-21 | Bristol-Myers Squibb Company | Tablet formulation for p38 inhibitor and method |
CA2799926A1 (en) * | 2010-05-28 | 2011-12-01 | Biocryst Pharmaceuticals, Inc. | Heterocyclic compounds as janus kinase inhibitors |
CN103012439B (zh) * | 2012-11-15 | 2015-03-11 | 沈阳药科大学 | 苯甲酰基取代的噻唑并[3,2-b]-1,2,4-三嗪衍生物及其应用 |
ES2616025T3 (es) * | 2013-03-11 | 2017-06-09 | Bristol-Myers Squibb Company | Pirrolotriazinas como inhibidores de canales de iones potasio |
ES2616026T3 (es) * | 2013-03-11 | 2017-06-09 | Bristol-Myers Squibb Company | Pirrolopiridazinas como inhibidores de canales de iones potasio |
US9050345B2 (en) * | 2013-03-11 | 2015-06-09 | Bristol-Myers Squibb Company | Pyrrolotriazines as potassium ion channel inhibitors |
JP6473146B2 (ja) * | 2013-10-11 | 2019-02-20 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | ピロロトリアジンキナーゼ阻害剤 |
WO2015081783A1 (zh) * | 2013-12-06 | 2015-06-11 | 江苏奥赛康药业股份有限公司 | 吡咯并[2,1-f][1,2,4]三嗪类衍生物及其制备方法和用途 |
US20190060286A1 (en) | 2016-02-29 | 2019-02-28 | University Of Florida Research Foundation, Incorpo | Chemotherapeutic Methods |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
ES2927715T3 (es) | 2017-10-05 | 2022-11-10 | Fulcrum Therapeutics Inc | Inhibidores de la quinasa p38 reducen la expresión de dux4 y de los genes que le siguen para el tratamiento de la FSHD |
CN108516977A (zh) * | 2018-07-10 | 2018-09-11 | 刘凤娟 | 一种用于治疗恶性肿瘤的map激酶抑制剂的合成方法 |
CN112028892B (zh) * | 2020-07-29 | 2022-12-16 | 天津全和诚科技有限责任公司 | 4-氨基-吡咯并三嗪衍生物在制备抗肺纤维化制剂中的应用 |
CN112094219B (zh) * | 2020-09-10 | 2022-08-05 | 广东莱佛士制药技术有限公司 | 一种制备钾离子竞争性阻滞剂中间体的方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2163399A1 (en) * | 1994-11-24 | 1996-05-25 | Katsuhiro Kawano | Triazine derivative, chymase activity inhibitor and nitric oxide production inhibitor |
WO1999024033A1 (en) * | 1997-11-12 | 1999-05-20 | Shionogi & Co., Ltd. | Method for the treatment of disorders associated with apoptosis using n-heterocyclic glyoxylamide compounds |
CN1351498B (zh) * | 1999-05-21 | 2012-08-15 | 布里斯托尔-迈尔斯斯奎布公司 | 激酶的吡咯并三嗪抑制剂 |
-
2001
- 2001-11-07 PL PL01366376A patent/PL366376A1/xx not_active Application Discontinuation
- 2001-11-07 PT PT01992298T patent/PT1363910E/pt unknown
- 2001-11-07 EP EP01992298A patent/EP1363910B1/en not_active Expired - Lifetime
- 2001-11-07 GE GE5243A patent/GEP20063915B/en unknown
- 2001-11-07 EE EEP200300227A patent/EE200300227A/xx unknown
- 2001-11-07 CA CA002429628A patent/CA2429628A1/en not_active Abandoned
- 2001-11-07 HU HU0303897A patent/HUP0303897A2/hu unknown
- 2001-11-07 BR BR0115446-0A patent/BR0115446A/pt not_active IP Right Cessation
- 2001-11-07 WO PCT/US2001/049982 patent/WO2002040486A2/en active IP Right Grant
- 2001-11-07 AT AT01992298T patent/ATE318820T1/de not_active IP Right Cessation
- 2001-11-07 DK DK01992298T patent/DK1363910T3/da active
- 2001-11-07 NZ NZ525334A patent/NZ525334A/en unknown
- 2001-11-07 DE DE60117607T patent/DE60117607T2/de not_active Expired - Lifetime
- 2001-11-07 MX MXPA03004290A patent/MXPA03004290A/es active IP Right Grant
- 2001-11-07 IL IL15557001A patent/IL155570A0/xx unknown
- 2001-11-07 ES ES01992298T patent/ES2259051T3/es not_active Expired - Lifetime
- 2001-11-07 JP JP2002543494A patent/JP2004522713A/ja active Pending
- 2001-11-07 AU AU2002232760A patent/AU2002232760B2/en not_active Ceased
- 2001-11-07 AU AU3276002A patent/AU3276002A/xx active Pending
- 2001-11-07 CZ CZ20031370A patent/CZ20031370A3/cs unknown
- 2001-11-07 KR KR1020037006661A patent/KR100847605B1/ko not_active IP Right Cessation
- 2001-11-07 SK SK540-2003A patent/SK5402003A3/sk unknown
- 2001-11-07 YU YU37903A patent/YU37903A/sh unknown
- 2001-11-07 CN CNA018189970A patent/CN1622946A/zh active Pending
- 2001-11-13 MY MYPI20015207A patent/MY127066A/en unknown
- 2001-11-16 PE PE2001001141A patent/PE20020819A1/es not_active Application Discontinuation
- 2001-11-16 AR ARP010105381A patent/AR032637A1/es unknown
-
2003
- 2003-04-21 BG BG107750A patent/BG107750A/bg unknown
- 2003-05-14 IS IS6816A patent/IS6816A/is unknown
- 2003-05-16 NO NO20032229A patent/NO20032229L/no not_active Application Discontinuation
- 2003-06-16 HR HR20030485A patent/HRP20030485A2/hr not_active Application Discontinuation
-
2004
- 2004-01-19 HK HK04100424A patent/HK1057555A1/xx not_active IP Right Cessation
-
2006
- 2006-06-01 CY CY20061100698T patent/CY1105250T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1363910B1 (en) | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors | |
US6670357B2 (en) | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors | |
AU2002232760A1 (en) | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors | |
EP1503996B1 (en) | Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors | |
KR101025675B1 (ko) | 키나제 억제제로서 유용한 피롤로-트리아진 아닐린 화합물 | |
US7642257B2 (en) | Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors | |
KR20080107408A (ko) | 키나제 억제제로서 유용한 피롤로트리아진 아닐린 전구약물화합물 | |
US7388009B2 (en) | Heteroaryl-substituted pyrrolo-triazine compounds useful as kinase inhibitors | |
ZA200303786B (en) | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA9A | Suspended patent application procedure at request of an applicant |